We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Ginkgo Biloba Extract in Mild Cognitive Impairment and Cerebrovascular Insufficiency

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00446485
First Posted: March 13, 2007
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Professor of Neurology Vida Demarin, MD, PhD, Milsing d.o.o.
  Purpose
The purpose of the study is to determine weather Ginkgo biloba standardized extract (24% ginkoflavonoglicozides and 6% terpenes) is effective in treatment of cognitive and concentration impairment

Condition Intervention Phase
Mild Cognitive Impairment Cerebrovascular Insufficiency Drug: Ginkgo biloba standardized extract 24/6 Drug: Ginkgo Biloba standardized extract 24/6 Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

Resource links provided by NLM:


Further study details as provided by Professor of Neurology Vida Demarin, MD, PhD, Milsing d.o.o.:

Primary Outcome Measures:
  • Changes of MDRS [ Time Frame: 6 months ]
  • Changes of VFT [ Time Frame: 6 months ]
  • Changes of CGI [ Time Frame: 6 months ]
  • Changes of SCAG [ Time Frame: 6 months ]
  • Changes of MMSE [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Changes of TCD, and color Doppler of carotid arteries [ Time Frame: 6 months ]
  • Changes of platelets, hematocrit, prothrombin time, and activated partial tromboplastin time [ Time Frame: 6 months ]
  • Changes of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides [ Time Frame: 6 months ]
  • Safety will be assessed according to occurrence of adverse events during the trial [ Time Frame: 6 months ]

Enrollment: 90
Study Start Date: May 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Ginkgo Biloba standardized extract 24/6
Drug: Ginkgo biloba standardized extract 24/6
tablets, 120 mg/day (60 mg two times daily) during 6 months
Drug: Ginkgo Biloba standardized extract 24/6
tablets, 60 mg/day during 6 months
Placebo Comparator: 3
placebo
Drug: placebo
placebo during 6 months

Detailed Description:
Inclusion criteria is cerebrovascular insufficiency MNSE>20. 90 patients are divided into three groups randomly. First group is being administered 120 mg ginkgo biloba extract, second group 60 mg of the extract and the third group has being administered placebo during the period of 6 months. Methods used for evaluation are SCAG, MMSE, MDRS, VFT, CGI, TCD and color Doppler of carotid arteries. Methods used for follow up safety include: routine blood tests, biochemical tests, neurologic and physical examination, vital signs and ECG.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • cerebrovascular insufficiency and mild cognitive disorder (MMSE=20-28)

Exclusion Criteria:

  • pregnancy
  • cognitive disorder caused by psychological, metabolic endocrine nutritional and heart disorder
  • alcohol or drug abuse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00446485


Locations
Croatia
University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29
Zagreb, Croatia, 10000
Sponsors and Collaborators
Milsing d.o.o.
Investigators
Principal Investigator: Vida Demarin, MD PHD University Department of Neurology, Sestre milosrdnice University Hospital, Vinogradska 29, HR-10000 Zagreb, Croatia
  More Information

Responsible Party: Professor of Neurology Vida Demarin, MD, PhD, MD, PhD, FAAN, FAHA, FESO Fellow of Croatian Academy of Sciences and Arts Professor of Neurology, Milsing d.o.o.
ClinicalTrials.gov Identifier: NCT00446485     History of Changes
Other Study ID Numbers: MIL-001
First Submitted: March 12, 2007
First Posted: March 13, 2007
Last Update Posted: October 12, 2017
Last Verified: September 2015

Keywords provided by Professor of Neurology Vida Demarin, MD, PhD, Milsing d.o.o.:
ginkgo biloba
cerebrovascular insufficiency
mild cognitive impairment
concentration impairment

Additional relevant MeSH terms:
Cognitive Dysfunction
Cerebrovascular Disorders
Cognition Disorders
Neurocognitive Disorders
Mental Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases